LJ570

Item no.	DCC-DC33576-250mg
Manufacturer	DCChemicals
CASRN	2252488-69-8
Amount	250 mg
Quantity options	100 mg 1 g 250 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	>98%
Smiles	O=C([C@H](CC1C=CC(C2C=CC=CC=2)=CC=1)OC1C=CC(C2C=CC=CC=2)=CC=1)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	2252488-69-8
Similar products	2252488-69-8
Available
Manufacturer - Applications	LJ570 is the first PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation. LJ570 is a potent partial agonist of both PPARα and γ subtypes. LJ570 inhibited the Cdk5-mediated phosphorylation of PPARγ at serine 273 that is currently considered the mechanism by which some PPARγ partial agonists exert antidiabetic effects similar to thiazolidinediones, without showing their typical side effects. LJ570 may be useful for treatment of dyslipidemic type 2 diabetes.
Molecular Weight	394, 46

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 250 mg

available

Delivery expected until 3/5/2026

Express Delivery: Save 3 days

Compare

Add to wishlist

Get an offer